Fig. 6.

The ratio of basophils activated by the stimulation of TLR1–TLR9. We analyzed peripheral basophils in healthy subjects (n = 27), patients with type 1 autoimmune pancreatitis (AIP, n = 40), patients with alcoholic chronic pancreatitis (ACP, n = 8), patients with bronchial asthma (n = 10), and patients with atopic dermatitis (n = 10). Basophils were stimulated with the TLR1–9 ligands, Pam₃CSK4 (400 ng/mL, InvivoGen, San Diego, CA, USA), HKLM (10⁸ cells/mL, InvivoGen), poly:IC (50 μg/mL, Sigma, St. Louis, MO, USA), LPS (1 μg/mL, Sigma), FLA-ST (10 μg/mL, InvivoGen), FSL-1 (5 μg/mL, InvivoGen), imiquimod (5 μg/mL, InvivoGen), ssRNA40/LyoVec (5 μg/mL, InvivoGen), or ODN2006 (10 μg/mL, AdipoGen, San Diego, CA, USA), respectively. Data are presented as the mean ± standard error of the mean. Statistical comparisons of quantitative data were carried out by the Tukey–Kramer test. Differences were considered to be significant when the value of P was less than 0.05 (P < 0.05)